Neurosearch A/S (NEUR.CO) Says to Cut Workforce by a Fifth, To Concentrate Resources Behind Main Product Huntington's Disease Drug Huntexil  
1/11/2011 6:45:18 AM

Reuters -- Danish biopharma company Neurosearch (NEUR.CO) is to cut costs and 20 percent of its workforce to concentrate resources behind its main product under development, Huntington's disease drug Huntexil.